Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia

NCT00937859 is registered in ClinicalTrials.gov with Serenity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00937859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia
Lead sponsor
Serenity Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2009
Completion date
July 31, 2010
Enrollment
301 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nocturia